OGN
HEALTHCAREOrganon & Co
AI Insight
What's Moving OGN Today?
No stock-specific AI insight has been generated for OGN yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$5.68$13.49
$13.46
Fundamentals
Market Cap$3.5B
P/E Ratio14.4
EPS$0.93
Dividend Yield0.60%
Dividend / Share$0.08
ROE34.1%
Profit Margin4.0%
Debt / Equity—
Trading
Volume189K
Avg Volume (10D)—
Shares Outstanding262.6M
OGN News
33 articles- Organon Canada and Henlius Expand Access to Denosumab Treatments With Launch of BILDYOS® (denosumab injection) and TUZEMTY® (denosumab injection), Biosimilars to PROLIA and XGEVAYahoo Finance·Jun 23, 2026
- Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should KnowYahoo Finance·Jun 22, 2026
- Organon wins rights to first U.S. hormone-free copper IUD in 40 yearsStock Titan·Jun 22, 2026
- Organon Completes Agreement to License MIUDELLA®, Sebela Pharmaceuticals’ Hormone-Free Intrauterine DeviceYahoo Finance·Jun 22, 2026
- Samsung Bioepis, Organon expand Stelara biosimilar partnership to CanadaKBR·Jun 19, 2026
- Arletta Pharma Solutions Appoints Steve van Os, MD, as Chief Medical OfficerYahoo Finance·Jun 19, 2026
- Samsung Bioepis and Organon Expand Agreement to Commercialize PYZCHIVA®, a Biosimilar Referencing STELARA® in CanadaBusinesskorea·Jun 18, 2026
- Organon and Samsung Bioepis Expand Agreement to Commercialize PYZCHIVA® (ustekinumab), a Biosimilar Referencing STELARA® (ustekinumab) in CanadaYahoo Finance·Jun 18, 2026
- Organon, Samsung Bioepis add sixth biosimilar for CanadaStock Titan·Jun 18, 2026
- Is TOFIDENCE’s Expanded CRS and COVID Label Altering The Investment Case For Organon (OGN)?Yahoo Finance·Jun 16, 2026
- Organon (OGN) director Shalini Sharp receives 17,857 phantom stock units as cash-settled awardStock Titan·Jun 15, 2026
- Organon (OGN) director receives phantom stock award, lifting holdings above 81,000 unitsStock Titan·Jun 15, 2026
- Organon (OGN) director awarded 17,857 phantom stock units under savings planStock Titan·Jun 15, 2026
- Organon (OGN) Stock After New TOFIDENCE Approval A Fresh Look At Valuation And Recovery PotentialYahoo Finance·Jun 15, 2026
- Organon Wins FDA Nod to Expand TOFIDENCE Use in Severe CRS & COVID-19Yahoo Finance·Jun 12, 2026
- Organon Secures US Food and Drug Administration Approval Expanding Indications for TOFIDENCE® (tocilizumab-bavi) in Cytokine Release Syndrome (CRS) and Pediatric COVID-19Yahoo Finance·Jun 10, 2026
- Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on ItYahoo Finance·Jun 9, 2026
- Investors Heavily Search Organon & Co. (OGN): Here is What You Need to KnowYahoo Finance·May 29, 2026
- Organon Audit Cleared And New Data Put Valuation And Risks In FocusYahoo Finance·May 25, 2026
- Hanmi Pharmaceutical Faz Parceria com a Organon para Exportação de Terapias de Combinação para o Sudeste AsiáticoGlobeNewswire Inc.·May 22, 2026
- Hanmi Pharmaceutical se asocia con Organon para exportar terapias combinadas al Sudeste AsiáticoGlobeNewswire Inc.·May 22, 2026
- Hanmi Pharmaceutical Partners with Organon to Export Combination Therapies to Southeast AsiaMacau Business·May 21, 2026
- Organon to Present New Research on Access and Value at ISPOR 2026Yahoo Finance·May 15, 2026
- India’s pharma industry is going global. But can it catch up to China?Pharmavoice·May 13, 2026
- Organon Buyout By Sun Pharma Shifts Focus To Cash Value And TimingYahoo Finance·May 7, 2026
- Lilly, Gilead lead pharma’s M&A boomPharmavoice·May 7, 2026
- Deal Dispatch: Sirius XM Mulls Purchase Of iHeartMedia, Uber Buys FlyTaxi, Wren Kitchens BankruptcyBenzinga·May 1, 2026
- Organon (OGN)’s Investors React Strongly as Sun Pharma Bets Big on Specialty Drug ExpansionYahoo Finance·May 1, 2026
- Organon (NYSE:OGN) Misses Q1 CY2026 Revenue EstimatesYahoo Finance·Apr 30, 2026
- Jim Cramer Says “Organon’s Done” Upon a Caller’s InquiryYahoo Finance·Apr 30, 2026
- Halper Sadeh LLC is Investigating Whether OGN, XOMA, RMAX, SLNO are Obtaining Fair Deals for their ShareholdersGlobeNewswire Inc.·Apr 28, 2026
- Stock Market Today, April 27: Organon Shares Surge After Sun Pharma Agrees to Acquire Company in All Cash DealThe Motley Fool·Apr 27, 2026
- Sun Pharma Nears Final Offer For Organon In Largest Overseas BetBenzinga·Apr 10, 2026
All 33 articles loaded
Price Data
Open$13.46
Previous Close$13.45
Day High$13.46
Day Low$13.45
52 Week High$13.49
52 Week Low$5.68
52-Week Range
$5.68$13.49
$13.46
Fundamentals
Market Cap$3.5B
P/E Ratio14.4
EPS$0.93
Dividend Yield0.60%
Dividend / Share$0.08
ROE34.1%
Profit Margin4.0%
Debt / Equity—
Trading
Volume189K
Avg Volume (10D)—
Shares Outstanding262.6M
About Organon & Co
Organon & Co. is an American pharmaceutical company headquartered in Jersey City, New Jersey. Organon specializes in the following core therapeutic fields: reproductive medicine, contraception, psychiatry, Hormone replacement therapy (HRT), and anesthesia. The company sells to international markets.
HEALTHCAREDRUG MANUFACTURERS - GENERAL
Company Details
Security TypeCommon Stock
ExchangeNYSE
CurrencyUSD
Round Lot—
SICDRUG MANUFACTURERS - GENERAL
CIK—
Composite FIGI—
Share Class FIGI—